PARP inhibitorPhase 3 trialInvestigational
PARP inhibitor
How it works
Blocks the repair of DNA damage in cancer cells, causing them to die.
Cancer types
Prostate Cancer— Patients with BRCA mutations
Efficacy
Studies show that PARP inhibitors can improve overall survival in around 30% of patients with BRCA mutations.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Testing Trastuzumab Deruxtecan for Recurrent Ovarian Cancer | Ovarian Cancer | phase-2 | — | Source → |
| Combining PARP Inhibitors and Platinum May Enhance Lung Cancer Treatment | Lung Cancer | lab-study | — | Source → |
| PARP Inhibitor Talazoparib Shows Promise in Treating Breast and Ovarian Cancers | Breast Cancer | review | Talazoparib has the highest potency (IC = 0.57 nM), which is 4-10 times lower than that of other PARP inhibitors. | Source → |
| DRG2 levels predict response to PARP inhibitors in prostate cancer cells | Prostate Cancer | lab-study | — | Source → |
| New Test for Cancer Patients May Help with PARP Inhibitor Therapy | Breast Cancer | lab-study | — | Source → |
| Olaparib and Abiraterone Combination Therapy for Prostate Cancer | Prostate Cancer | review | — | Source → |
| PARP Inhibitor Resistance Linked to BRCA1 Gene Mutations | Ovarian Cancer | lab-study | — | Source → |
| Combining Cancer Treatments May Improve Lung Cancer Outcomes | Lung Cancer | lab-study | Tumor doubling times increased to 1.6-fold (H446) and 2.2-fold (H69) under combination treatment. | Source → |
| Mutations in Prostate Cancer Tissue Affect PARP Inhibitor Therapy | Prostate Cancer | lab-study | — | Source → |
| Spliceosome Gene Mutations in Leukemia Linked to PARP Inhibitor Sensitivity | Leukemia | lab-study | — | Source → |
| Combining Hormonal Therapies with PARP Inhibitors for Prostate Cancer | Prostate Cancer | phase-3 | Emerging data suggested that the radiographic progression-free survival (rPFS) was significantly longer in the PARP inhibitor combined with NHT group versus the placebo plus NHT group. | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.